Cargando…

Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer

Prostate-specific membrane antigen (PSMA) is present in the tumor-associated neovasculature of many cancer types. Current data in ovarian cancer are limited and controversial; thus, the aim of this study was to investigate PSMA expression in a larger and homogenous patient cohort. This might lead to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofstetter, Gerda, Grech, Christina, Pils, Dietmar, Pammer, Johannes, Neudert, Barbara, Pötsch, Nina, Baltzer, Pascal, Traub-Weidinger, Tatjana, Seebacher, Veronika, Aust, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025859/
https://www.ncbi.nlm.nih.gov/pubmed/35455669
http://dx.doi.org/10.3390/jpm12040551
_version_ 1784690979142369280
author Hofstetter, Gerda
Grech, Christina
Pils, Dietmar
Pammer, Johannes
Neudert, Barbara
Pötsch, Nina
Baltzer, Pascal
Traub-Weidinger, Tatjana
Seebacher, Veronika
Aust, Stefanie
author_facet Hofstetter, Gerda
Grech, Christina
Pils, Dietmar
Pammer, Johannes
Neudert, Barbara
Pötsch, Nina
Baltzer, Pascal
Traub-Weidinger, Tatjana
Seebacher, Veronika
Aust, Stefanie
author_sort Hofstetter, Gerda
collection PubMed
description Prostate-specific membrane antigen (PSMA) is present in the tumor-associated neovasculature of many cancer types. Current data in ovarian cancer are limited and controversial; thus, the aim of this study was to investigate PSMA expression in a larger and homogenous patient cohort. This might lead to further studies investigating the use of imaging and therapeutic modalities targeting PSMA. Eighty patients with advanced stage high-grade serous ovarian cancers were included. Using immunohistochemistry, PSMA and CD31, a marker for endothelial cells, were examined in whole tissue sections. Percentage and intensity of PSMA expression were determined in the neovasculature. Expression levels were correlated with clinicopathological parameters and survival. Low (≤10%), medium (20–80%), and high (≥90%) PSMA expression was found in 14, 46, and 20 ovarian cancer samples, respectively. PSMA expression was confined to tumor-associated neovasculature and significantly correlated with progression-free (HR 2.24, 95% CI 1.32–3.82, p = 0.003) and overall survival (HR 2.73, 95% CI 1.41–5.29, p = 0.003) in multivariate models, considering age, FIGO stage, and residual disease. This is the first study showing a clinical relevance for PSMA in patients with ovarian cancer. PSMA was detected in the vast majority of cancer samples and showed an impact on survival.
format Online
Article
Text
id pubmed-9025859
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90258592022-04-23 Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer Hofstetter, Gerda Grech, Christina Pils, Dietmar Pammer, Johannes Neudert, Barbara Pötsch, Nina Baltzer, Pascal Traub-Weidinger, Tatjana Seebacher, Veronika Aust, Stefanie J Pers Med Article Prostate-specific membrane antigen (PSMA) is present in the tumor-associated neovasculature of many cancer types. Current data in ovarian cancer are limited and controversial; thus, the aim of this study was to investigate PSMA expression in a larger and homogenous patient cohort. This might lead to further studies investigating the use of imaging and therapeutic modalities targeting PSMA. Eighty patients with advanced stage high-grade serous ovarian cancers were included. Using immunohistochemistry, PSMA and CD31, a marker for endothelial cells, were examined in whole tissue sections. Percentage and intensity of PSMA expression were determined in the neovasculature. Expression levels were correlated with clinicopathological parameters and survival. Low (≤10%), medium (20–80%), and high (≥90%) PSMA expression was found in 14, 46, and 20 ovarian cancer samples, respectively. PSMA expression was confined to tumor-associated neovasculature and significantly correlated with progression-free (HR 2.24, 95% CI 1.32–3.82, p = 0.003) and overall survival (HR 2.73, 95% CI 1.41–5.29, p = 0.003) in multivariate models, considering age, FIGO stage, and residual disease. This is the first study showing a clinical relevance for PSMA in patients with ovarian cancer. PSMA was detected in the vast majority of cancer samples and showed an impact on survival. MDPI 2022-03-31 /pmc/articles/PMC9025859/ /pubmed/35455669 http://dx.doi.org/10.3390/jpm12040551 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hofstetter, Gerda
Grech, Christina
Pils, Dietmar
Pammer, Johannes
Neudert, Barbara
Pötsch, Nina
Baltzer, Pascal
Traub-Weidinger, Tatjana
Seebacher, Veronika
Aust, Stefanie
Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
title Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
title_full Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
title_fullStr Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
title_full_unstemmed Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
title_short Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
title_sort prostate-specific membrane antigen (psma) expression in tumor-associated neovasculature is an independent prognostic marker in patients with ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025859/
https://www.ncbi.nlm.nih.gov/pubmed/35455669
http://dx.doi.org/10.3390/jpm12040551
work_keys_str_mv AT hofstettergerda prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT grechchristina prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT pilsdietmar prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT pammerjohannes prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT neudertbarbara prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT potschnina prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT baltzerpascal prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT traubweidingertatjana prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT seebacherveronika prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer
AT auststefanie prostatespecificmembraneantigenpsmaexpressionintumorassociatedneovasculatureisanindependentprognosticmarkerinpatientswithovariancancer